Evaluating PI-RADS lesions and clinically significant prostate cancer in Black and Asian men: a PREVENT randomized clinical trial secondary analysis.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: PI-RADS 3-5 lesions, 88 (13%) were Black and 36 (6%) were Asian
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[SOURCE OF FUNDING] Supported by the NCI (5R01CA241758-05). [TRIAL REGISTRATION] Registered at ClinicalTrials.gov (NCT04843566, https://clinicaltrials.gov/study/NCT04843566).
[PURPOSE] Non-White patients are poorly represented in prostate cancer trials.
APA
Driscoll C, Handa N, et al. (2025). Evaluating PI-RADS lesions and clinically significant prostate cancer in Black and Asian men: a PREVENT randomized clinical trial secondary analysis.. Research square. https://doi.org/10.21203/rs.3.rs-6905600/v1
MLA
Driscoll C, et al.. "Evaluating PI-RADS lesions and clinically significant prostate cancer in Black and Asian men: a PREVENT randomized clinical trial secondary analysis.." Research square, 2025.
PMID
40630527 ↗
Abstract 한글 요약
[PURPOSE] Non-White patients are poorly represented in prostate cancer trials. MRI PI-RADS scoring was developed in primarily White populations, but prostate cancer differs in non-White men. We aimed to explore differences in PI-RADS calibration for Asian and Black men.
[MATERIALS AND METHODS] This is a secondary analysis of PREVENT, a multi-institutional study of infection rates for transrectal vs. transperineal biopsy. We compared cancer detection for self-identifying Asian and Black men. We compared detection rates on a per-person basis, stratified by index PI-RADS lesion, to White men, using Fisher's exact and logistic regression.
[RESULTS] Of 665/752 trial patients with PI-RADS 3-5 lesions, 88 (13%) were Black and 36 (6%) were Asian. Black men were younger at diagnosis with increased rates of overall (70% vs. 43%%, =0.004) and clinically significant prostate cancer (60% vs. 27%, =0.003) and Asian men had decreased rates of overall (0% vs. 47%, =0.004) and clinically significant prostate cancer (0% vs. 27%, =0.003) in PI-RADS 3 lesions compared to White men. On multivariable regression, Black men with PI-RADS 3/4 lesions had higher odds of overall (OR 1.17, =0.009) and clinically significant prostate cancer (OR 1.20, =0.004) and Asian men had lower odds of overall (OR 0.79, =0.01) but not clinically significant prostate cancer (OR 0.94, =0.5).
[CONCLUSIONS] Black men with PI-RADS 3/4 lesions had 20% higher odds of clinically significant prostate cancer than White men while all PI-RADS 3 lesions in Asian men were negative. These findings suggest PI-RADS may require differential interpretation when assessing prostate cancer risk in non-White men.
[SOURCE OF FUNDING] Supported by the NCI (5R01CA241758-05).
[TRIAL REGISTRATION] Registered at ClinicalTrials.gov (NCT04843566, https://clinicaltrials.gov/study/NCT04843566).
[MATERIALS AND METHODS] This is a secondary analysis of PREVENT, a multi-institutional study of infection rates for transrectal vs. transperineal biopsy. We compared cancer detection for self-identifying Asian and Black men. We compared detection rates on a per-person basis, stratified by index PI-RADS lesion, to White men, using Fisher's exact and logistic regression.
[RESULTS] Of 665/752 trial patients with PI-RADS 3-5 lesions, 88 (13%) were Black and 36 (6%) were Asian. Black men were younger at diagnosis with increased rates of overall (70% vs. 43%%, =0.004) and clinically significant prostate cancer (60% vs. 27%, =0.003) and Asian men had decreased rates of overall (0% vs. 47%, =0.004) and clinically significant prostate cancer (0% vs. 27%, =0.003) in PI-RADS 3 lesions compared to White men. On multivariable regression, Black men with PI-RADS 3/4 lesions had higher odds of overall (OR 1.17, =0.009) and clinically significant prostate cancer (OR 1.20, =0.004) and Asian men had lower odds of overall (OR 0.79, =0.01) but not clinically significant prostate cancer (OR 0.94, =0.5).
[CONCLUSIONS] Black men with PI-RADS 3/4 lesions had 20% higher odds of clinically significant prostate cancer than White men while all PI-RADS 3 lesions in Asian men were negative. These findings suggest PI-RADS may require differential interpretation when assessing prostate cancer risk in non-White men.
[SOURCE OF FUNDING] Supported by the NCI (5R01CA241758-05).
[TRIAL REGISTRATION] Registered at ClinicalTrials.gov (NCT04843566, https://clinicaltrials.gov/study/NCT04843566).
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Machine learning integrating MRI and clinical features predicts early recurrence of hepatocellular carcinoma after resection.
- Patient-Perceived Overall Side Effect Bother at and After Cancer Treatment Discontinuation: An Analysis Using Commercial Cancer Trial Data.
- The Barriers and Enablers to Participation in Oncology Clinical Trials for Ethnically Diverse Communities: A Qualitative Systematic Review Using Metaethnography.
- A novel real-world data methodology for lymphoma outcome classification: the real-world Lugano study.
- Updates on Clinical Trials and Molecular Characteristics of Locally Advanced and Oligometastatic Renal Cell Carcinoma.